Browsing by Author "Tusquets Trias de Bes, Ignacio"

Sort by: Order: Results:

  • Peremiquel-Trillas, Paula; Tusquets Trias de Bes, Ignacio; Castaño Vinyals, Gemma; Kogevinas, Manolis; Costas, Laura (Elsevier, 2019)
    BACKGROUND: Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the ...
  • Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Rial, Abora; Cos, Maria Lourdes; Campodarve, Isabel; Rodriguez-Morera, Jaime; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Springer, 2019)
    PURPOSE: The most frequent adverse effects of aromatase inhibitors (AI) are arthralgia and bone loss induction. These reduce the quality of life of patients and their adherence to the treatment. This study evaluates the ...
  • Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Casamayor, Guillem; Cos, Maria Lourdes; Rial, Abora; Rodriguez-Morera, Jaime; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Elsevier, 2018)
    Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The ...
  • Tamborero Noguera, David; Rubio Pérez, Carlota, 1990-; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets Trias de Bes, Ignacio; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Torres, Carmen de; Dienstmann, Rodrigo; González-Pérez, Abel; López Bigas, Núria (BioMed Central, 2018)
    While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a ...
  • Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: ...
  • Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (Impact Journals, 2014)
    NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional ...
  • Rodríguez Sanz, Maria, 1984-; Prieto-Alhambra, Daniel; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Garrigos, L.; Albanell Mestres, Joan; Martinez-García, Maria; González, I.; Martos, Tamara; Díez Pérez, Adolfo; Tusquets Trias de Bes, Ignacio; Nogués Solan, Francesc Xavier (Sociedad Española de Investigación Ósea y del Metabolismo Mineral, 2015)
    Objetivos: El objetivo del estudio fue analizar los cambios en la densidad mineral ósea (DMO) a lo largo del tratamiento con inhibidores de aromatasa (IA) en la práctica clínica y evaluar la asociación entre el gen CYP11A1 ...
  • Carracedo, Alma; Egervari, Kristof; Salido, Marta; Rojo, Federico; Arumí, Montserrat; Corominas Torres, Josep Maria; Corzo, Cristina; Tusquets Trias de Bes, Ignacio; Espinet Solà, Blanca; Rovira Guerín, Ana; Albanell Mestres, Joan; Szollosi, Zoltan; Serrano Figueras, Sergi; Solé Ristol, Francesc (BioMed Central, 2009)
  • Pineda-Moncusí, Marta; Garcia Giralt, Natàlia; Díez Pérez, Adolfo; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Prieto-Alhambra, Daniel; Nogués Solan, Francesc Xavier (Wiley, 2020)
    Aromatase inhibitors have been associated with accelerated bone loss and an increased risk of osteoporotic fractures. Currently, bisphosphonates are recommended to reduce fracture risk in these patients. The aim of this ...
  • Muntasell i Castellví, Aura, 1972-; Cabo, Mariona; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; López-Botet, Miguel (Frontiers, 2017)
    Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy ...
  • Lope, Virginia; Gracia Lavedan, Esther; Pumarega Rodríguez, José Antonio; Tusquets Trias de Bes, Ignacio; Kogevinas, Manolis; Castaño Vinyals, Gemma; Pollan, Marina (Elsevier, 2016)
    BACKGROUND: Accumulated exposure to hormones and growth factors during early life may influence the future risk of breast cancer (BC). This study examines the influence of childhood-related, socio-demographic and anthropometric ...
  • Conde Estévez, David; Echeverría Esnal, David; Tusquets Trias de Bes, Ignacio; Albanell Mestres, Joan (Oxford University Press, 2015)
  • Rodríguez Sanz, Maria, 1984-; Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Martos, Tamara; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rodriguez-Morera, Jaime; Díez Pérez, Adolfo; Albanell Mestres, Joan; Nogués Solan, Francesc Xavier (Elsevier, 2016)
    INTRODUCTION: Patients with breast cancer under aromatase inhibitor (AI) treatment often develop osteoporosis and their average bone loss rate is twice that of natural reduction during menopause, increasing fracture risk. ...
  • Gómez-Acebo, Inés; Tusquets Trias de Bes, Ignacio; Castaño Vinyals, Gemma; Kogevinas, Manolis; Llorca, Javier (Public Library of Science (PLoS) , 2016)
    INTRODUCTION: The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled ...
  • Pastor-Barriuso, Roberto; Fernandez, Mariana F.; Castaño Vinyals, Gemma; Whelan, Denis ; Pérez-Gómez, Beatriz; Llorca, Javier; Villanueva Belmonte, Cristina; Guevara, Marcela; Molina-Molina, Jose Manuel; Artacho-Cordón, Francisco; Barriuso-Lapresa, Laura; Tusquets Trias de Bes, Ignacio; Dierssen Sotos, Trinidad; Aragonés, Núria; Olea, Nicolás; Kogevinas, Manolis; Pollan, Marina (National Institute of Environmental Health Sciences, 2016)
    BACKGROUND: Most studies on endocrine-disrupting chemicals and breast cancer have focused on single compounds and have produced inconclusive findings. OBJECTIVES: We assessed the combined estrogenic effects of mixtures of ...
  • Pineda-Moncusí, Marta; García-Pérez, Miguel Angel; Rial, Abora; Casamayor, Guillem; Cos, Maria Lourdes; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Cano, Antonio; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Elsevier, 2018)
    To evaluate the vitamin D status of postmenopausal women with early estrogen-receptor-positive breast cancer and to compare it with that of healthy postmenopausal women from the same Mediterranean region. STUDY DESIGN AND ...